| Quantity | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg | 5 mg, 10 mg | 5 mg, 10 mg | 125 U | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes[1] | CRT, an iron peptide mimic, can bind to apo-transferrin (apo-Tf). CRT can be used to modify nanoparticles, and enhances drug delivery efficiency[1] | Hemocyanin is a large copper-containing respiratory protein. Hemocyanin is an important non-specific innate immune defense molecule with phenoloxidase, antiviral, antibacterial, hemolytic, and antitumor activities[1] | Phi29 DNA Polymerase is a mesophilic DNA polymerase cloned from Bacillus subtilis phage Phi29 | Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake[1]... Read More |